March 2024
1. MUROYA D, Morimitsu Y, Nakamura K, Hayashi K, et al
   Hidden metastatic lung tumour diagnosed by AI.
   Lancet. 2024;403:1290.
   

   >> Share

   
   
2. EDERHY S, Cadranel J, Granger C, Hammoudi N, et al
   Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve after tyrosine kinase inhibitor treatment.
   Lancet. 2024;403:860-861.
   

   >> Share

   
   January 2024
3. PAZ-ARES L, Mehta B, Wang Y, Obiozor C, et al
   Sotorasib in KRAS(G12C) mutated lung cancer - Authors' reply.
   Lancet. 2024;403:145-146.
   

   >> Share

   
   
4. OLIVIER T, Prasad V
   Sotorasib in KRAS(G12C) mutated lung cancer.
   Lancet. 2024;403:145.
   

   >> Share

   
   
5. HANNA GG, McDonald F
   SBRT for oligoprogressive disease: using the evidence to maximise the benefits.
   Lancet. 2024;403:122-124.
   

   >> Share

   
   December 2023
6. CHU Q, Perrone F, Greillier L, Tu W, et al
   Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
   Lancet. 2023;402:2295-2306.
   

   >> Share

   
   
7. LEE YCG
   Pembrolizumab plus chemotherapy for pleural mesothelioma.
   Lancet. 2023;402:2266-2267.
   

   >> Share

   
   
8. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
   Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
   Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
   

   >> Share

   
   November 2023
9. SALMAN M, Fernandez Crespo R, Judah G
   Impact of messaging informed by behavioural science on uptake of targeted lung health checks: a service evaluation.
   Lancet. 2023;402 Suppl 1:S82.
   

   >> Share

   
   July 2023
10. BROOKS ED
    Safe and effective systemic therapy for early-stage non-small-cell lung cancer.
    Lancet. 2023 Jul 18:S0140-6736(23)01464-2. doi: 10.1016/S0140-6736(23)01464.
    

    >> Share

    
    
11. CHANG JY, Lin SH, Dong W, Liao Z, et al
    Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
    Lancet. 2023 Jul 18:S0140-6736(23)01384-3. doi: 10.1016/S0140-6736(23)01384.
    

    >> Share

    
    
12. O'SULLIVAN H, Popat S
    Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible.
    Lancet. 2023 Jul 6:S0140-6736(23)00807-3. doi: 10.1016/S0140-6736(23)00807.
    

    >> Share

    
    
13. LEE SM, Schulz C, Prabhash K, Kowalski D, et al
    First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled stu
    Lancet. 2023 Jul 6:S0140-6736(23)00774-2. doi: 10.1016/S0140-6736(23)00774.
    

    >> Share

    
    April 2023
14. SLATER S, Cunningham D
    Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer.
    Lancet. 2023 Apr 14:S0140-6736(23)00767-5. doi: 10.1016/S0140-6736(23)00767.
    

    >> Share

    
    February 2023
15. GOLDBERG SB, Herbst RS
    The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.
    Lancet. 2023 Feb 9:S0140-6736(23)00288-X. doi: 10.1016/S0140-6736(23)00288.
    

    >> Share

    
    
16. DE LANGEN AJ, Johnson ML, Mazieres J, Dingemans AC, et al
    Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial.
    Lancet. 2023 Feb 7:S0140-6736(23)00221-0. doi: 10.1016/S0140-6736(23)00221.
    

    >> Share

    
    December 2022
17. ADAMS SJ, Stone E, Baldwin DR, Vliegenthart R, et al
    Lung cancer screening.
    Lancet. 2022 Dec 20:S0140-6736(22)01694-4. doi: 10.1016/S0140-6736(22)01694.
    

    >> Share

    
    September 2022
18. THE LANCET
    COPD: from an end-stage disease to lifelong lung health.
    Lancet. 2022;400:863.
    

    >> Share

    
    April 2022
19. SAJI H, Okada M, Tsuboi M, Nakajima R, et al
    Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
    Lancet. 2022;399:1607-1617.
    

    >> Share

    
    
20. THE LANCET
    Cancer care: beyond survival.
    Lancet. 2022;399:1441.
    

    >> Share

    
    September 2021
21. FELIP E, Altorki N, Zhou C, Csoszi T, et al
    Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)02098.
    

    >> Share

    
    
22. GAINOR JF
    Adjuvant PD-L1 blockade in non-small-cell lung cancer.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)02100.
    

    >> Share

    
    July 2021
23. BAAS P, Scherpereel A, Nowak AK, Oukessou A, et al
    Heterogeneity of treatment effects in malignant pleural mesothelioma - Authors' reply.
    Lancet. 2021;398:302.
    

    >> Share

    
    
24. DI MAIO M, Tagliamento M
    Heterogeneity of treatment effects in malignant pleural mesothelioma.
    Lancet. 2021;398:301-302.
    

    >> Share

    
    
25. THAI AA, Solomon BJ, Sequist LV, Gainor JF, et al
    Lung cancer.
    Lancet. 2021 Jul 14. pii: S0140-6736(21)00312.
    

    >> Share

    
    January 2021
26. TREASURE T, Macbeth F, Farewell V, Williams NR, et al
    The fallacy of large survival gains from lung metastasectomy in colorectal cancer.
    Lancet. 2021;397:97-98.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share